April 11, 2018

ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

YONKERS, N.Y., April 11, 2018 (GLOBE NEWSWIRE) -- **ContraFect Corporation** (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the presentation of data on its lead drug candidate CF-301 at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held from April 21-24, 2018, in Madrid, Spain.

The presentations include results from *in vitro*, *in vivo* and microbiologic surveillance studies of ContraFect's lead lysin CF-301, which is currently being evaluated in a Phase 2 clinical trial as a potential treatment for *Staphylococcus aureus (Staph aureus*) bacteremia, including endocarditis. Topics to be covered include CF-301's synergy with standard of care antibiotics (SOC) including optimal timing of CF-301 administration relative to SOC and suppression of resistance to SOC; anti-biofilm activity against 'human' biofilm; and activity against contemporary clinical isolates of *Staph aureus* collected at centers in Europe. The presentations include one oral session and four poster sessions.

"We are pleased to return to ECCMID to present new data on the activity of CF-301, our first-in-class lysin candidate. We are excited to present for the first time, experimental results demonstrating CF-301's ability to eradicate biofilms formed in the clinical setting of a catheter-related bloodstream infection" said Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development at ContraFect. "In addition, we will present important data from studies using the rabbit infectious endocarditis model which further confirms the potent ability of CF-301, dosed at or below the Phase 2 dose, to potentiate bactericidal activity through synergy with anti-staphylococcal antibiotics. These findings further support the superiority design of our ongoing study to evaluate CF-301 used in addition to SOC antibiotics. We continue to look forward to announcing top-line results from this Phase 2 trial in the fourth quarter of 2018," continued Dr. Cassino.

Presentation Details:

Presentation Title: Efficacy of lysin CF-301 in addition to daptomycin or vancomycin in a

rabbit model of infective endocarditis due to methicillin-resistant *Staph aureus* (MRSA)
Oral Presentation Day & Time: Sunday, April 22, 2018, 5:46 p.m. – 5:56 p.m. CEST (11:46 a.m. – 11:56 a.m. EDT)
Abstract Number: #O0581
Session Title: Drug combinations: pre-clinical evidence

Presentation Title*:* Translational study of the antibiofilm activity of lysin CF-301 in an infected hemodialysis catheter from patient with suspected *Staph aureus* bacteremia
Session Day & Time: Monday, April 23, 2018, 12:30 p.m. – 1:30 p.m. CEST (6:30 a.m. – 7:30 a.m. EDT)
Abstract Number: #P1435
Session Title: Biofilms I - Gram-positive pathogens

Presentation Title*:* European surveillance study of CF-301 activity against contemporary *Staph aureus* isolates from Italy, Greece, and Hungary
Session Day & Time: Tuesday, April 24, 2018, 12:30 p.m. – 1:30 p.m. CEST (6:30 a.m. – 7:30 a.m. EDT)
Abstract Number: #P2450
Session Title: Phages and therapeutic antibodies

Presentation Title*:* Optimal timing of the Co-administration of lysin CF-301 with daptomycin in a rabbit model of infective endocarditis due to MRSA
Session Day & Time: Tuesday, April 24, 2018, 12:30 p.m. – 1:30 p.m. CEST (6:30 a.m. – 7:30 a.m. EDT)
Abstract Number: #P2451
Session Title: Phages and therapeutic antibodies

Presentation Title*:* Lysin CF-301 exhibits a low propensity for decreased susceptibility and prevents daptomycin resistance in a rabbit model of *Staph aureus* infective endocarditis
Session Day & Time: Tuesday, April 24, 2018, 12:30 p.m. – 1:30 p.m. CEST (6:30 a.m. – 7:30 a.m. EDT)
Abstract Number: #P2452
Session Title: Phages and therapeutic antibodies

The abstracts can be accessed through the ECCMID website. Following the meeting, the presentation posters will be available on the ContraFect website.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant *Staph aureus)* and influenza. ContraFect's lead product candidate, CF-301, is currently in a Phase 2 clinical trial for the treatment of *Staphylococcus aureus* bacteremia, including endocarditis and is the first lysin to enter clinical studies in the U.S. ContraFect is also conducting research focused on the

discovery of lysins to target Gram-negative bacteria.

About CF-301:

CF-301 is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staph aureus, a major cause of blood stream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staph aureus bacteremia. It has a novel, rapid, and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm infections. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect. It is the first lysin to enter clinical studies in the U.S.

Forward-Looking Statements:

This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding CF-301 experimental data or results, our ability to discover and develop protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, our ability to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses, whether our initial product candidates can treat antibiotic-resistant infections such as MRSA and influenza, our ability to discover new lysins targeting Gram-negative bacteria, the potential for CF-301 to be a treatment for *Staph aureus* bacteremia, including endocarditis, and statements made regarding oral and poster sessions. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contacts:

Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: mmessinger@contrafect.com

Matthew Shinseki
Stern Investor Relations
Tel: 212-362-1200
Email: matthew@sternir.com

Source: ContraFect Corporation